Indegene Stock Rises on Kotak Upgrade, Growth Outlook

  Published 9 months ago

Indegene shares rise 1.4% as Kotak raises fair value to 700 rupees, citing FY26 growth recovery and strong pipeline.

  • Stock hits 3.5% intraday high; Kotak maintains 'buy' rating amid stable demand despite tariff risks.
  • Double-digit FY26 revenue growth expected from digital biopharma services, led by North America revenue.
  • Average analyst rating 'hold' with 610 rupee median target; stock down 2% year-to-date.

You might like these

MMRDA Awards 4-Year SI Contract for Infrastructure Monitoring

JioBlackRock Gains Mutual Fund License

Indian Equities Rally Amid Global Relief

Laurus Labs Q1 Profit Soars 1144%

ENBD to Acquire RBL Bank

Travel Food Services IPO: Key Details and Market Impact

Keystone FY26 H1: Sales & Redevelopment

News that matters the most ⚡